Analysis of the Effect of Sintilimab Combined with the DA-EPOCH-R Regimen in the Treatment of Diffuse Large B-Cell Lymphoma
Objective To explore the specific effects of combining cyclophosphamide,doxorubicin,etoposide,vincristine,prednisone,and rituximab(DA-EPOCH-R regimen)with sintilimab in the treatment of diffuse large B cell lymphoma(DLBCL).Methods A total of 82 DLBCL cases admitted and treated at the Oncology Department of Nanyang Central Hospital from January 2020 to December 2023 were selected.Based on different treatment regimens,they were divided into a study group(n=41,sintilimab+DA-EPOCH-R regimen)and a control group(n=41,DA-EPOCH-R regimen alone).The efficacy,serum markers,immune indicators,and complications were analyzed.Results The objective response rate(ORR)and disease control rate(DCR)in the study group were higher than those in the control group,with statistically significant differences(P<0.05).Before treatment,there were no statistically significant differences in serum markers and immune indicators between the two groups(P>0.05).After treatment,the serum markers and immune indicators in both groups decreased,and the levels in the study group were lower than those in the control group,with statistically significant differences (P<0.05). There was no statistically significant difference in the incidence of complications between the two groups after treatment (P>0.05). Conclusion During the treatment of DLBCL,the combination of the DA-EPOCH-R regimen with sintilimab can achieve relatively ideal clinical efficacy,improve serum markers and immune indicators,and does not increase the incidence of complications,making it clinically significant.
SintilimabDA-EPOCH-R regimendiffuse large b-cell lymphomaefficacy
万方数据
维普
